Sara Coelho

Dr. Sara Coelho

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2021 in Current Problems in Cancer
Verified
Journal Article
Closed access
IMInês Moreira
Inês Moreira
SCSara Coelho
Sara Coelho
ÂRÂngelo Rodrigues
Ângelo Rodrigues
APAna Sofia Patrão
Ana Sofia Patrão
MMMaria Joaquina Maurício
Maria Joaquina Maurício

30 October 2020 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
DODiana Oliveira
Diana Oliveira
TBTeresa Brito
Teresa Brito
AEAna Elias
Ana Elias
MCMarta Carreira
Marta Carreira
MSMariana Serino
Mariana Serino
PLPatricia Lourenco
Patricia Lourenco
Diabetes mellitus (DM) predicts ominous outcomes in acute pulmonary embolism (PE). The influence of gender on the prognostic impact of DM in PE is unknown. We did a retrospective analysis of a cohort of patients hospitalized with PE between 2006 and 2013. The exclusion criteria were age <18, non-pulmonary veins thromboembolism, recurrent PE, chronic thromboembolic pulmonary hypertension, no radiologic confirmation of PE, and active neoplasia. The primary endpoint was all-cause mortality. The follow-up was from diagnosis until October 2017. We assessed the prognostic impact of DM using a multivariate Cox regression analysis. The analysis was stratified according to gender. The interaction between gender and DM in the outcome of patients with PE was tested. We studied 577 PE patients (median age 65 years, 36.9% men, 19.8% diabetic). The genders were similar regarding the prevalence of DM, the extension and location of PE, and the thrombolytic therapy or brain natriuretic peptide (BNP) value. Diabetics presented higher all-cause mortality (Hazard ratio (HR) = 2.33 (95% confidence Interval (CI) 1.513.61)) when compared with non-diabetics. However, when analysis was stratified according to gender, DM was independently associated with a worse prognosis only in women (HR = 2.31 (95% CI 1.453.65)), while in men the HR was 1.10 (95% CI 0.592.04). The interaction between gender and DM was significant (p = 0.04). Gender influences the prognostic impact of DM in acute PE. Diabetic women with PE have twice the long-term mortality risk, while DM is not mortality-associated in men.

1 January 2021 in Critical Care Science
Verified
Journal Article
Open access
PDF file
SCSara Coelho
Sara Coelho
TRTeresa Ribeiro
Teresa Ribeiro
IPIsabel Pereira
Isabel Pereira
DDDelfim Duarte
Delfim Duarte
AAAna Afonso
Ana Afonso
FFFilomena Faria
Filomena Faria
To ascertain the cumulative incidence of acute organ failure and intensive care unit admission in cancer patients. This was a single-center prospective cohort study of adult cancer patients admitted for unscheduled inpatient care while on systemic cancer treatment. Between August 2018 and February 2019, 10,392 patients were on systemic treatment, 358 had unscheduled inpatient care and were eligible for inclusion, and 285 were included. The mean age was 60.9 years, 50.9% were male, and 17.9% of patients had hematologic cancers. The cumulative risk of acute organ failure was 39.6% (95%CI: 35 - 44), and that of intensive care unit admission among patients with acute organ failure was 15.0% (95%CI: 12 - 18). On admission, 62.1% of patients were considered not eligible for artificial organ replacement therapy. The median follow-up time was 9.5 months. Inpatient mortality was 17.5%, with an intensive care unit mortality rate of 58.8% and a median cohort survival of 134 days (95%CI: 106 - 162). In multivariate analysis, acute organ failure was associated with 6-month postdischarge mortality (HR 1.6; 95%CI: 1.2 - 2.2). The risk of acute organ failure in cancer patients admitted for unscheduled inpatient care while on systemic treatment was 39.6%, and the risk of intensive care unit admission was 15.0%. Acute organ failure in cancer patients was an independent poor prognostic factor for inpatient hospital mortality and 6-month survival.

23 June 2023 in Current Oncology
Verified
Journal Article
Open access
PDF file
IRInês Brandão Rego
Inês Brandão Rego
SCSara Coelho
Sara Coelho
PSPatrícia Miguel Semedo
Patrícia Miguel Semedo
JCJoana Cavaco-Silva
Joana Cavaco-Silva
LTLaetitia Teixeira
Laetitia Teixeira
LCLuis Costa
Luis Costa
Background: The increased focus on quality indicators (QIs) and the use of clinical registries in real-world cancer studies have increased compliance with therapeutic standards and patient survival. The European Society of Breast Cancer Specialists (EUSOMA) established QIs to assess compliance with current standards in breast cancer care. Methods: This retrospective study is part of H360 Health Analysis and aims to describe compliance with EUSOMA QIs in breast cancer management in different hospital settings (public vs. private; general hospitals vs. oncology centers). A set of key performance indicators (KPIs) was selected based on EUSOMA and previously identified QIs. Secondary data were retrieved from patients’ clinical records. Compliance with target KPIs in different disease stages was compared with minimum and target EUSOMA standards. Results: A total of 259 patient records were assessed. In stages I, II, and III, 18 KPIs met target EUSOMA standards, 5 met minimum standards, and 8 failed to meet minimum standards. Compliance with KPIs varied according to the type of hospital (particularly regarding diagnosis) and disease stage. Although small differences were found in KPI compliance among institutions, several statistical differences were found among treatment KPIs according to disease stage, particularly in stage III. Conclusions: This study represents the first assessment of the quality of breast cancer care in different hospital settings in Portugal and shows that, although most QIs meet EUSOMA standards, there is room for improvement. Differences have been found across institutions, particularly between oncology centers and general hospitals, in diagnosis and compliance with KPIs among disease stages. Stage III showed the greatest variability in compliance with treatment KPIs, probably related to the lower specificity of the guidelines in this disease stage.

1 May 2017 in Porto Biomedical Journal
Verified
Journal Article
Open access
SCSara Coelho
Sara Coelho
HMHelena Magalhães
Helena Magalhães
JCJorge Correia
Jorge Correia
AMAdriana Magalhães
Adriana Magalhães
PLPatrícia Lourenço
Patrícia Lourenço
Polymyalgia rheumatica is an inflammatory rheumatologic condition that occurs frequently in the elderly. It has been, although infrequently, associated with malignancies, in a synchronous or closely time-related appearance. In such circumstances, polymyalgia rheumatica is considered to be a paraneoplastic syndrome and is often atypical in presentation with poor response to glucocorticoid treatment. We report the case of a 79-year-old woman in which the simultaneous diagnosis of polymyalgia rheumatica and lung adenocarcinoma was made. Rheumatologic symptoms responded partially to anti-inflammatory medication, with further response to lung cancer targeted chemotherapy.

16 December 2020 in Pharmacy
Verified
Journal Article
Open access
PDF file
José António Ferraz GonçalvesJosé António Ferraz Gonçalves
José António Ferraz Gonçalves
FSFilipa Sousa
Filipa Sousa
LALucy Alves
Lucy Alves
PLPatrícia Liu
Patrícia Liu
SCSara Coelho
Sara Coelho
Alfentanil is used for chronic pain relief in palliative care. However, there is a dearth of data on its use. For this reason, a decision was made to review the use of alfentanil in palliative care. Retrospective study was carried out in a palliative care service. The files of patients who received alfentanil as an intravenous or subcutaneous continuous infusion for pain relief, between January 2018 and April 2019. In total, 111 patients received alfentanil out of 113 admissions. Of them, 56 were male, and the median age was 70 years. The median number of days on alfentanil was 6 (range 1 to 129). The most frequent primary reasons for switching to alfentanil was uncontrolled pain in 52 (46%) patients and renal impairment in 24 (21%) patients. The median 24-h initial dose of alfentanil was 4 mg (1–20), and the median final 24-h dose of alfentanil was 5 mg (1–60), (p < 0.001). The initial 24-h median number of rescue doses was 2 (0–8), and the final median number of rescue doses was 1 (0 to 8), (p = 0.025). In 56 patients who were on alfentanil for at least 7 days, the dose decreased in 3 (5%), remained stable in 10 (18%) and increased in 43 (77%). The patient on alfentanil for 129 days maintained the same dose throughout that period. Alfentanil can be a useful second-line opioid. The induction of tolerance does not seem to be particularly rapid with alfentanil.